Make more informed purchasing decisions with our new product availability and delivery estimate feature, now available on all product pages, in your cart, and during checkout.
Sign In
New to STEMCELL?
Register for an account to quickly and easily purchase products online and for one-click access to all educational content.
Thank you for your interest in this product.
Please provide us with your contact information and your local representative
will contact you with a customized quote. Where appropriate, they can also assist you with a(n):
Estimated delivery time for your area
Product sample or exclusive offer
In-lab demonstration
By submitting this form, you are providing your consent to STEMCELL Technologies Canada Inc. and its subsidiaries and affiliates (“STEMCELL”) to collect and use your information, and send you newsletters and emails in accordance with our privacy policy. Please contact us with any questions that you may have. You can unsubscribe or change your email preferences at any time.
Interleukin-8 (IL-8) is a member of the CXC subfamily of chemokines and is produced by leukocytic cells (monocytes, T cells, neutrophils, and natural killer cells) and non-leukocytic somatic cells (endothelial cells, fibroblasts, and epithelial cells), with the most prominent source being monocytes and macrophages. Its production is induced by inflammatory stimuli, such as IL-1. IL-8, also known as CXCL8, activates neutrophils inducing chemotaxis, exocytosis, and the respiratory burst (Baggiolini & Clark-Lewis; Mukaida). IL-8 is considered one of the most potent neutrophil chemoattractants in inflammation and binds to two different chemokine receptors on leukocytes: the G protein-coupled receptors CXCR1 and CXCR2 (Hoffmann et al.; de Oliveira et al.). IL-8 has angiogenic effects on human intestinal microvascular endothelial cells in vitro that are mediated by CXCR2 (Heidemann et al.). IL-8 is reported to promote breast cancer progression by increasing cell invasion, angiogenesis, and metastasis and has been reported to be involved in regulating breast cancer stem-like cells (Singh et al.). IL-8 also has proangiogenic properties in inflammatory diseases of the conjunctiva, cornea, iris, retina, and orbit (Ghasemi et al.). It was also shown that a major T cell effector function in human newborns is IL-8 production, which has the potential to activate antimicrobial neutrophils and gamma/delta T cells (Gibbons et al.). A variety of human pathogens, such as HIV and Mycobacterium tuberculosis, have been shown to induce IL-8 production by monocytes and macrophages (Friedland et al.; Meddows-Taylor et al.).
Subtype
Cytokines
Alternative Names
CXC motif ligand 8, GCP-1, Granulocyte chemotactic protein 1, Interleukin-8, MDNCF, Monocyte-derived neutrophil chemotactic factor, NAF, NAP-1, Neutrophil activating factor, SCYB8, Small inducible cytokine subfamily B member 8
Cell Type
Airway Cells, Endothelial Cells, Keratinocytes, Macrophages, Monocytes, NK Cells
(A) The biological activity of Human Recombinant IL-8 (CXCL8) was tested by its ability to mobilize Ca2+ in CHO-K1/Gα15/hCXCR1 cells (human Gα15 and human CXCR1 stably expressed in CHO-K1 cells). Ca2+ mobilization was measured using a fluorometric assay method. The EC50 is defined as the effective concentration of the growth factor at which Ca2+ mobilization is at 50% of maximum. The EC50 in the example above is less than 0.15 μg/mL.
(B) 2 μg of Human Recombinant IL-8 (CXCL8) was resolved with SDS-PAGE under reducing (+) and non-reducing (-) conditions and visualized by Coomassie Blue staining. Human Recombinant IL-8 (CXCL8) has a predicted molecular mass of 8.9 kDa.
This product is designed for use in the following research area(s) as part
of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we
offer to support each research area.
STEMCELL TECHNOLOGIES INC.’S QUALITY MANAGEMENT SYSTEM IS CERTIFIED TO ISO 13485. PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED.